| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/HEPR.12229 |
| P698 | PubMed publication ID | 24033816 |
| P2093 | author name string | Yasuharu Imai | |
| Sumio Kawata | |||
| Norio Hayashi | |||
| Naoki Hiramatsu | |||
| Tetsuo Takehara | |||
| Yuki Makino | |||
| Yasushi Matsumoto | |||
| Nobuyuki Kajiwara | |||
| Tsugiko Oze | |||
| Kazuto Fukuda | |||
| Sachiyo Kogita | |||
| Takumi Igura | |||
| Yoshiyuki Sawai | |||
| Keiko Irishio | |||
| Masanori Nakahara | |||
| Rui Mizumoto | |||
| Sinichiro Zushi | |||
| P2860 | cites work | Review and management of drug interactions with boceprevir and telaprevir | Q24628716 |
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | Q29620702 | ||
| Response-guided telaprevir combination treatment for hepatitis C virus infection | Q34632295 | ||
| Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C | Q36371508 | ||
| Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection | Q36645372 | ||
| Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. | Q36670297 | ||
| Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death | Q42983596 | ||
| Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest | Q43033968 | ||
| Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan | Q43039581 | ||
| The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects | Q43746740 | ||
| Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters | Q47248395 | ||
| Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group | Q47819933 | ||
| Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. | Q50550265 | ||
| Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. | Q50557485 | ||
| A high-throughput SNP typing system for genome-wide association studies | Q57269468 | ||
| P433 | issue | 12 | |
| P921 | main subject | ribavirin | Q421862 |
| P304 | page(s) | 1165-1171 | |
| P577 | publication date | 2014-01-07 | |
| P1433 | published in | Hepatology Research | Q15752035 |
| P1476 | title | Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. | |
| P478 | volume | 44 |
| Q41209439 | Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment? |
| Q38500364 | Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C. |
| Q35169059 | Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection |
| Q38435340 | Telaprevir-induced renal impairment: three clinical cases and a review of the literature |
| Q42205243 | eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? |
Search more.